Skip to main content

SYSTEMATIC REVIEW article

Front. Neurol.
Sec. Neuromuscular Disorders and Peripheral Neuropathies
Volume 15 - 2024 | doi: 10.3389/fneur.2024.1456559

Efficacy and safety of different doses of vamorolone in boys with Duchenne muscular dystrophy: a systematic review and network meta-analysis

Provisionally accepted
QIN WANG QIN WANG Yaqin Zeng Yaqin Zeng *Linna Jiao Linna Jiao *Jianli He Jianli He *Baoyi Li Baoyi Li *Yihua Guo Yihua Guo *Zhibin Song Zhibin Song *
  • Zhongshan Xiaolan People's Hospital, Zhongshan, China

The final, formatted version of the article will be published soon.

    Background and Objectives:Several recent clinical studies have indicated that vamorolone is comparable in effectiveness to glucocorticosteroids for treating Duchenne muscular dystrophy (DMD).However,there is a lack of extensive data regarding the efficacy and safety of various doses of vamorolone.We conducted a study to evaluate the efficacy of different doses of vamorolone in boys with DMD,and compare the safety of vamorolone vs glucocorticosteroids ,prednisone or deflazacort in boys with DMD.Methods:We performed systematic searches of the PubMed,Embase,and Cochrane Library databases for vamorolone,glucocorticosteroids,prednisone or deflazacort in boys with DMD.We assessed statistical heterogeneity across trials based on the Newcastle Ottawa scale (NOS )tool test and I 2 values,and mean differences were pooled using the random-effects model.We used traditional Meta-Analysis to evaluate efficacy and safety of vamorolone 6.0 mg/kg/d vs.vamorolone 2.0 mg/kg/d and vamorolone vs.prednisone.A network meta-analysis was applied to estimated the safety of vamorolone in comparison to glucocorticosteroids,prednisone and deflazacort.Our meta-analysis were performed using Revman 5.4 software,and our network meta-analysis were performed using Stata/MP 18.0.Results:In the meta-analysis,a total of 193 patients were analyzed across four clinical trials(97 patients receiving vamorolone 2mg/kg per day;96 patients receiving vamorolone 2mg/kg per day).We observed that there were statistically significant differences in boys with DMD between vamorolone 6.0 mg/kg/d and vamorolone 2.0 mg/kg/d in TTSTANDV (MD=0.03,95%CI=0.00-0.06,P=0.04), TTRWV(MD=0.13,95%CI=0.08-0.19,P<0.01), 6MWT(MD=24.54, P=0.02),TTCLIMBV (MD=0.04,95%CI=0.01-0.06,P=0.009),no significant difference in BMI z score(MD=0.09, 95%CI=-0.03-0.20,P=0.13).Indirect comparisons derived from network meta-analysis did not show significant differences among vamorolone ,glucocorticosteroids ,prednisone and deflazacort in BMI z score.Our findings implied that boys with DMD who took vamorolone 6 mg/kg daily instead of 2 mg/kg daily may be safer and have superior motor function. However,more large sample randomized controlled trials are needed to confirm our results.

    Keywords: Duchenne muscular dystroph, vamorolone, Glucocorticosteroids, Prednisone, deflazacort Glossary

    Received: 01 Jul 2024; Accepted: 09 Aug 2024.

    Copyright: © 2024 WANG, Zeng, Jiao, He, Li, Guo and Song. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Yaqin Zeng, Zhongshan Xiaolan People's Hospital, Zhongshan, China
    Linna Jiao, Zhongshan Xiaolan People's Hospital, Zhongshan, China
    Jianli He, Zhongshan Xiaolan People's Hospital, Zhongshan, China
    Baoyi Li, Zhongshan Xiaolan People's Hospital, Zhongshan, China
    Yihua Guo, Zhongshan Xiaolan People's Hospital, Zhongshan, China
    Zhibin Song, Zhongshan Xiaolan People's Hospital, Zhongshan, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.